-
Mashup Score: 0
Adults with pulmonary arterial hypertension (PAH) have a new treatment available with the FDA approval of sotatercept (Winrevair; Merck), an activin signaling inhibitor biologic.
Source: www.ajmc.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 0Report: Sotatercept improves clinical outcomes in PAH, but unlikely to be cost-effective - 4 month(s) ago
When added to background therapy for pulmonary arterial hypertension, sotatercept improves 6-minute walk distance and WHO functional class vs. placebo, according to an evidence report by the Institute for Clinical and Economic Review. However, models in the Institute for Clinical and Economic Review (ICER) report suggested it would exceed typical cost-effectiveness thresholds.
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 0Report: Sotatercept improves clinical outcomes in PAH, but unlikely to be cost-effective - 5 month(s) ago
When added to background therapy for pulmonary arterial hypertension, sotatercept improves 6-minute walk distance and WHO functional class vs. placebo, according to an evidence report by the Institute for Clinical and Economic Review. However, models in the Institute for Clinical and Economic Review (ICER) report suggested it would exceed typical cost-effectiveness thresholds.
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 0Report: Sotatercept improves clinical outcomes in PAH, but unlikely to be cost-effective - 5 month(s) ago
When added to background therapy for pulmonary arterial hypertension, sotatercept improves 6-minute walk distance and WHO functional class vs. placebo, according to an evidence report by the Institute for Clinical and Economic Review. However, models in the Institute for Clinical and Economic Review (ICER) report suggested it would exceed typical cost-effectiveness thresholds.
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
Adults with pulmonary arterial hypertension ( #PAH ) have a new treatment available with the FDA approval of #sotatercept (Winrevair; Merck), an activin signaling inhibitor biologic. Learn more here: https://t.co/QFJd4OqF3s https://t.co/XkeQjCcrPF